We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Apretude

News List

FDA Approves Apretude Drugs
December 27, 2021
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (Pfizer) and Shionogi Limited (Shionogi) as shareholders...
FDA approves ViiV Healthcare’s Apretude for HIV prevention Pharmaceutical-Business-Review
December 22, 2021
The long-acting injectable is indicated for use in adults and adolescents who are at risk of sexually acquiring HIV and test negative for HIV-1 before initiation.
First Long-Acting Injectable Approved for HIV PrEP drugs.com
December 21, 2021
The U.S. Food and Drug Administration has approved the first long-acting injectable treatment for HIV preexposure prophylaxis, which is given every two months and offers an alternative to daily oral medication, the agency announced Monday.